373 related articles for article (PubMed ID: 30447328)
1. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
Wilkinson ST; Sanacora G
Drug Discov Today; 2019 Feb; 24(2):606-615. PubMed ID: 30447328
[TBL] [Abstract][Full Text] [Related]
2. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID; Park LT; Zarate CA
CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
[TBL] [Abstract][Full Text] [Related]
3. Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders.
Hecking J; Davoudian PA; Wilkinson ST
Chronic Stress (Thousand Oaks); 2021; 5():24705470211020446. PubMed ID: 34124495
[TBL] [Abstract][Full Text] [Related]
4. GABA and glutamate systems as therapeutic targets in depression and mood disorders.
Kendell SF; Krystal JH; Sanacora G
Expert Opin Ther Targets; 2005 Feb; 9(1):153-68. PubMed ID: 15757488
[TBL] [Abstract][Full Text] [Related]
5. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
Abdallah CG; Sanacora G; Duman RS; Krystal JH
Annu Rev Med; 2015; 66():509-23. PubMed ID: 25341010
[TBL] [Abstract][Full Text] [Related]
6. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Dean RL; Hurducas C; Hawton K; Spyridi S; Cowen PJ; Hollingsworth S; Marquardt T; Barnes A; Smith R; McShane R; Turner EH; Cipriani A
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD011612. PubMed ID: 34510411
[TBL] [Abstract][Full Text] [Related]
7. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
Sanacora G; Treccani G; Popoli M
Neuropharmacology; 2012 Jan; 62(1):63-77. PubMed ID: 21827775
[TBL] [Abstract][Full Text] [Related]
8. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
Krystal JH; Sanacora G; Blumberg H; Anand A; Charney DS; Marek G; Epperson CN; Goddard A; Mason GF
Mol Psychiatry; 2002; 7 Suppl 1():S71-80. PubMed ID: 11986998
[TBL] [Abstract][Full Text] [Related]
9. A hypothesis of monoamine (5-HT) - Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery.
Li YF
Pharmacol Ther; 2020 Apr; 208():107494. PubMed ID: 31991195
[TBL] [Abstract][Full Text] [Related]
10. [Psychopharmacology of anxiety and depression: Historical aspects, current treatments and perspectives].
Javelot H
Ann Pharm Fr; 2016 Mar; 74(2):93-118. PubMed ID: 26472602
[TBL] [Abstract][Full Text] [Related]
11. Glutamatergic Modulators in Depression.
Henter ID; de Sousa RT; Zarate CA
Harv Rev Psychiatry; 2018; 26(6):307-319. PubMed ID: 29465478
[TBL] [Abstract][Full Text] [Related]
12. Ketamine and other potential glutamate antidepressants.
Dutta A; McKie S; Deakin JFW
Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
[TBL] [Abstract][Full Text] [Related]
13. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
Machado-Vieira R; Manji HK; Zarate CA
Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
[TBL] [Abstract][Full Text] [Related]
14. Glutamate modulators as novel interventions for mood disorders.
Mathew SJ; Keegan K; Smith L
Braz J Psychiatry; 2005 Sep; 27(3):243-8. PubMed ID: 16224615
[TBL] [Abstract][Full Text] [Related]
15. Role of calcium, glutamate and NMDA in major depression and therapeutic application.
Deutschenbaur L; Beck J; Kiyhankhadiv A; Mühlhauser M; Borgwardt S; Walter M; Hasler G; Sollberger D; Lang UE
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():325-33. PubMed ID: 25747801
[TBL] [Abstract][Full Text] [Related]
16. Dysfunctional hippocampal activity affects emotion and cognition in mood disorders.
Femenía T; Gómez-Galán M; Lindskog M; Magara S
Brain Res; 2012 Oct; 1476():58-70. PubMed ID: 22541166
[TBL] [Abstract][Full Text] [Related]
17. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.
Hashimoto K; Malchow B; Falkai P; Schmitt A
Eur Arch Psychiatry Clin Neurosci; 2013 Aug; 263(5):367-77. PubMed ID: 23455590
[TBL] [Abstract][Full Text] [Related]
18. [Ketamine, psilocybin, and rapid acting antidepressant: new promise for psychiatry?].
Bottemanne H; Claret A; Fossati P
Encephale; 2021 Apr; 47(2):171-178. PubMed ID: 33190819
[TBL] [Abstract][Full Text] [Related]
19. Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.
Pehrson AL; Sanchez C
Drug Des Devel Ther; 2015; 9():603-24. PubMed ID: 25653499
[TBL] [Abstract][Full Text] [Related]
20. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.
Duman RS; Sanacora G; Krystal JH
Neuron; 2019 Apr; 102(1):75-90. PubMed ID: 30946828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]